DocWire News Editors

DocwireNews

Cancer remains a leading cause of morbidity and mortality in the United States, and the cost of cancer care is projected to reach $156 billion in 2020. Since 2013, more than 45 novel cancer therapies have been approved, with more than 600 molecules in late-phase clinical trials. During a presentation at AMCP Annual Meeting 2018, Christina Link, PharmD, and Jake Chaffee, PharmD, both clinical managers at Blue Cross Blue Shield of Michigan, gave an overview of oncology treatment innovations.
Last year, the U.S. Food and Drug Administration approved the first two chimeric antigen receptor (CAR) T-cell therapies (tisagenlecleucel and axicabtagene ciloleucel), which collect patient immune cells, reengineer them, and reintroduce them into the body to target tumor cells. Another novel treatment option is CRISPR—a gene therapy technique in which genes in living cells can be modified or corrected to treat genetic causes of disease.
The goal of CAR-T therapy is complete remission (CR). Tisagenlecleucel led to 83% of patients achieving CR/CR with incomplete hematologic recovery. All patients achieved minimal residual disease-negative status. Axicabtagene ciloleucel resulted in 51% of patients achieving CR. The median duration of treatment was not reached for either therapy. Both CAR T-cell therapies have boxed warnings for cytokine release syndrome—a systemic inflammatory response syndrome—and neurological toxicities. The cost of CAR T-cell therapies can range from approximately $523,000 to $795,000 per case.
These innovative therapies with large price tags result in payment strategy challenges and require different management and payment models. Some of these payment models for innovative oncology agents include:
<ul>
<li>Bundled payments: Include single payments for defined episode of care or set of services; used in transplants, inpatient clinical episodes, and select oncology programs</li>
<li>Accountable care organizations and patient-centered medical homes: Payment is linked to effective management of population or episode of care</li>
<li>Value-based and outcomes-based contracting: Payment terms are tied to clinical circumstances, patient outcomes, or agreed-upon measures</li>
<li>Annuity payments: A series of payments are made at equal intervals</li>
</ul>
Site of care, biosimilars, and drug competition are areas to consider in oncology management. Alternative sites of care to the hospital outpatient setting are the member’s home, physician’s office, and ambulatory infusion center. Site of care consideration can lead to an $8,000 decrease in per-person, per-month costs; fewer emergency department (ED) encounters—including 18% fewer ED visits at 10 days and 28% fewer ED visits in 72 hours—and decreased physician visits. Biosimilars are providing competition at lower costs, and two agents have already been approved: tbo-filgrastim and filgrastim-sndz, which are used to treat neutropenia. Other biosimilar agents in the pipeline are for reference drugs trastuzumab, rituximab, bevacizumab, and pegfilgrastim.
Presentation S3: Digesting Cancer’s Alphabet Soup: Managing CAR-T, CRISPR and other Innovation in Oncology. AMCP Annual Meeting 2018.

Emily Menendez

Complete Response to Immunotherapy in HCC: Insights From IMbrave150

Hepatocellular Carcinoma

Anne Marie Morse, DO

Rob Dillard

Dr. Morse Talks About the Significance of World Sleep Day 2025

Sleep Disorders

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Latest News

CAR-T, CRISPR, and More Updates in Cancer Care and How to Pay for Them

AMCP 2018

Cancer remains a leading cause of morbidity and mortality in the United States, and the cost of cancer care is projected to reach $156 billion in 2020. Since 2013, more than ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe